Neuland Laboratories Limited (NEULANDLAB) — Corporate Action

· NSE 🔴 High Importance Neutral
Revenue: ₹2.02 L CrNet Profit: ₹36,399.84 Cr
📢 Key Event
Board approved FY2025-26 audited results, final dividend of ₹34/share, capacity expansion, and Dr. Futran's appointment pending AGM approval.
🔮 What's Next
2026-08-04
💡 Investor Takeaway
The company is investing ₹143.4 crores in expansion while returning ₹34/share dividend, signaling confidence in growth despite capital-intensive plans.

Neuland Laboratories reported FY2025-26 audited financials showing revenue of [amount not verified] and net profit of [amount not verified], with a proposed final dividend of ₹34 per share (340% payout). The board approved capacity expansion at Telangana Unit 1 requiring ₹143.4 crores investment, and appointed Dr. Mauricio Futran as Additional Director pending shareholder approval at the August 4 AGM.

📄 View Original Announcement (PDF)

About Neuland Laboratories Limited (NEULANDLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹21,284.79 Cr P/E: 71.0

View full NEULANDLAB stock details →

📡 Get AI alerts when NEULANDLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track NEULANDLAB — Free

📊 More NEULANDLAB filings

See all NEULANDLAB filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when NEULANDLAB files new disclosures

Track NEULANDLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track NEULANDLAB — Free

Free account · 2 AI queries/day